Brii Biosciences Future Growth
Future criteria checks 2/6
Brii Biosciences is forecast to grow earnings and revenue by 25.2% and 63.2% per annum respectively. EPS is expected to grow by 27.5% per annum. Return on equity is forecast to be -27.7% in 3 years.
Key information
25.2%
Earnings growth rate
27.5%
EPS growth rate
Biotechs earnings growth | 33.3% |
Revenue growth rate | 63.2% |
Future return on equity | -27.7% |
Analyst coverage | Low |
Last updated | 14 Feb 2024 |
Recent future growth updates
Recent updates
Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans
Nov 19Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation
Jul 26Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth
Jan 12We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely
Sep 20We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn
Mar 24Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 315 | -792 | N/A | N/A | 1 |
12/31/2025 | 207 | -817 | N/A | N/A | 1 |
12/31/2024 | 117 | -911 | N/A | N/A | 1 |
12/31/2023 | 417 | -175 | N/A | N/A | N/A |
9/30/2023 | 276 | -251 | N/A | N/A | N/A |
6/30/2023 | 134 | -327 | -720 | -581 | N/A |
3/31/2023 | 128 | -405 | -678 | -539 | N/A |
12/31/2022 | 122 | -484 | -636 | -496 | N/A |
9/30/2022 | 99 | -1,021 | -591 | -521 | N/A |
6/30/2022 | 75 | -1,558 | -546 | -546 | N/A |
3/31/2022 | 84 | -2,861 | -713 | -713 | N/A |
12/31/2021 | 93 | -4,164 | -880 | -879 | N/A |
9/30/2021 | 100 | -3,999 | -838 | -837 | N/A |
6/30/2021 | 107 | -3,835 | -796 | -794 | N/A |
3/31/2021 | 94 | -2,512 | -600 | -599 | N/A |
12/31/2020 | 82 | -1,190 | -404 | -404 | N/A |
12/31/2019 | 20 | -521 | -91 | -67 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2137 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2137 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2137 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2137's revenue (63.2% per year) is forecast to grow faster than the Hong Kong market (8% per year).
High Growth Revenue: 2137's revenue (63.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2137 is forecast to be unprofitable in 3 years.